On October 7, a research and analysis paper was published on British Medical Journal, with Professor He Jianxing and Professor Liang Wenhua of the SKLRD as the corresponding authors and the master candidate Zhao Yi as the primary first author. The research has included and analyzed 4,682 patients from 18 clinical researches and probed deeply into the best therapeutic plans for EGFR patients. First the paper pointed out that for the primary therapy for EGFR patients, the scheme of Gefitinib and chemotherapy has a therapeutic effect equivalent to the third-generation TKI and ranked top among all schemes for therapeutic effect. Second, it pointed out that the two schemes were respectively the best therapy for the two main types of mutation EGFR Del19 and L858R. The EGFR mutation is the main type of lung cancer, which accounts for 40-50% of all lung cancer cases of Asian patients. In recent years, there emerged a lot of new drugs and combined therapies, with disputes on their advantages and disadvantages. The research finding has provided the best therapy scheme for the large group of EGFR lung cancer patients and provided a strong evidence for clinicians to select the suitable scheme accurately from many options.